Shares of Venus Remedies surged about 6 per cent on the NSE following the receipt of tender from UNICEF for its antibiotic drug Ceftriaxone 1 mg.
According to Venus Remedies’ stock exchange disclosure, this follows the receipt of GMP (Good Manufacturing Practices) approval from UNICEF.
The stock of Venus Remedies traded at ₹374.50 on the NSE, higher by 5.69 per cent as of 10.06 am.
The company had declared its financial results for the quarter ended March 2024 recording its consolidated net profit at ₹10.51 crore as against ₹11.06 crore in the corresponding quarter last year.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.